Selumetinib shows promise in metastatic uveal melanoma.
Selumetinib shows promise in metastatic uveal melanoma.
复制标题
DOI：
10.1158/2159-8290.cd-nb2013-086
复制
发表时间：
2013-07-01
期刊：
影响因子：
28.2
通讯作者：
中科院分区：
文献类型：
--
作者：
Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease.
